Impact Of Chronic Hepatitis C Infectionand Liver Metastasis On Survival Outcome Of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer (nsclc) Patient Treated With First-Line Gefetinib In Real-World Practice

被引：0
|
作者：
Yao, Z. -H.
Liao, W. -Y.
Ho, C. -C.
Chen, K. -Y.
Shih, J. -Y.
Chen, J. -S.
Lin, Z. -Z.
Lin, C. -C.
Yang, J. -H.
Yu, C. -J.
机构：
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2016年 / 193卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A4272
引用
收藏
页数：1
相关论文
共 50 条
  • [31] First-Line Afatinib vs Gefitinib for Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: The LUX-Lung 7 Trial
    Aix, Santiago Ponce
    Park, Keunchil
    Tan, Eng-Huat
    O'Byrne, Kenneth
    Zhang, Li
    Boyer, Michael
    Mok, Tony
    Hirsh, Vera
    Yang, James Chih-Hsin
    Maerten, Angela
    Paz-Ares, Luis
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S203 - S204
  • [32] First-Line Dacomitinib versus Gefitinib in Advanced Non-Small-Cell Lung Cancer with EGFR Mutation Subgroups
    Wu, Y.
    Cheng, Y.
    Zhou, X.
    Lee, K. H.
    Nakagawa, K.
    Niho, S.
    Tsuji, F.
    Rosell, R.
    Corral, J.
    Migliorino, M. R.
    Pluzanski, A.
    Linke, R.
    Sbar, E.
    Wang, T.
    Zhang, H.
    Mok, T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1754 - S1754
  • [33] Age-Related Outcomes of First-Line Pembrolizumab in a Real-World Non-Small-Cell Lung Cancer (NSCLC) Cohort
    Dolter, S.
    Grosjean, H.
    Meyers, D.
    Javizian, O.
    Stukalin, I.
    Goutam, S.
    Morris, D.
    Bebb, D. G.
    Pabani, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S290 - S290
  • [34] Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer
    Shin, Ji Eun
    Jung, Hyun Ae
    Park, Sehhoon
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Shim, Byoung Yong
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [35] A potential new therapeutic option for patients with advanced EGFR mutation-positive non-small cell lung cancer in first-line setting
    Gridelli, Cesare
    Losanno, Tania
    JOURNAL OF THORACIC DISEASE, 2016, 8 (11) : E1520 - E1524
  • [36] Aumolertinib plus apatinib versus aumolertinib as first-line treatment in patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
    Zhang, Fan
    Hu, Yi
    Han, Xiao
    Hu, ZhiSong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [37] Overall Survival of Advanced Non-Small Cell Lung Cancer Treated with First-Line Afatinib: A Multicenter Real-World Study in Vietnam
    Pham, C. T. M.
    Truong, M. C.
    Do, T. A.
    Pham, P. C.
    Nguyen, H. T. T.
    Nguyen, K. T.
    Hoang, T. T. A.
    Le, A. T.
    Vuong, H. D. T.
    Nguyen, T. D. N.
    Dang, K. V.
    Nguyen, O. T.
    Luan, P. V.
    Nguyen, H. M.
    Vo, T. T. H.
    Do, K. H.
    Vu, T. H.
    Nguyen, H. T. T.
    Pham, T. V.
    Trinh, H. L.
    Nguyen, G. H.
    Nguyen, P. T. B.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S630 - S631
  • [38] A Real-World Study of Clinicopathological Characteristics and Survival Outcome in Advanced ALK-Positive Non-Small-Cell Lung Cancer
    Jin, Y.
    Hu, X.
    Chen, M.
    Chen, Y.
    Shi, X.
    Yu, X.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1952 - S1952
  • [39] First- and second-line treatment of non-small-cell lung cancer patients with EGFR mutation-positive tumors
    Reck, Martin
    Reinmuth, Niels
    Heigener, David F.
    LUNG CANCER MANAGEMENT, 2012, 1 (03) : 201 - 217
  • [40] Real-World Study of Patients With EGFR Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Treated With First-Line Osimertinib
    Nieva, J.
    Taylor, A.
    Servidio, L.
    Sun, P.
    Okhuoya, P.
    Horvat, P.
    Tolani, E.
    Magee, K.
    Mathur, R.
    Balakrishna, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1113 - S1113
12345